Galectin Therapeutics (GALT)
(Delayed Data from NSDQ)
$3.64 USD
+0.04 (1.11%)
Updated Apr 30, 2024 09:35 AM ET
4-Sell of 5 4
D Value B Growth B Momentum C VGM
Fundamental Charts
About Price to Cash Flow
The Price to Cash Flow ratio or P/CF is price divided by its cash flow per share. It's another great way to determine whether a company is undervalued or overvalued with the denominator being cash flow. One of the reasons why some investors prefer the P/CF ratio over the P/E ratio is because the net income of the cash flow portion rightly adds depreciation and amortization back in since these are not cash expenditures. In contrast, the net income that goes into the earnings portion of the P/E ratio does not add these in, thus artificially reducing the income and skewing the P/E ratio. Like the P/E ratio, a lower number is considered better. A value under 20 is generally considered good.
GALT 3.64 +0.04(1.11%)
Will GALT be a Portfolio Killer in April?
Zacks Investment Research is releasing its prediction for GALT based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for GALT
Galectin Therapeutics Inc. (GALT)'s Technical Outlook is Bright After Key Golden Cross
What Makes Galectin Therapeutics Inc. (GALT) a New Buy Stock
GALT: What are Zacks experts saying now?
Zacks Private Portfolio Services
Bears are Losing Control Over Galectin Therapeutics Inc. (GALT), Here's Why It's a 'Buy' Now
Catalyst Pharmaceuticals (CPRX) Q1 Earnings Miss, Revenues Up Y/Y
Other News for GALT
Madrigal: 2 Challenges To Overcome To Maintain NASH 'First Mover' Advantage
Galectin Therapeutics And 2 Other Penny Stocks Insiders Are Buying
Hepion ends Phase 2 study for NASH drug due to cash restraints
Wall Street Breakfast: The Week Ahead
Catalyst Watch: Boeing hearing, Bitcoin halving event and new eyes on Reddit